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Abstract
The terminology “gut-brain axis “points out a bidirectional relationship between the GI system and the central
nervous system (CNS). To date, several researches have shown that migraine is associated with some
gastrointestinal (GI) disorders such as Helicobacter pylori (HP) infection, irritable bowel syndrome (IBS), and celiac
disease (CD). The present review article aims to discuss the direct and indirect evidence suggesting relationships
between migraine and the gut-brain axis. However, the mechanisms explaining how the gut and the brain may
interact in patients with migraine are not entirely clear. Studies suggest that this interaction seems to be influenced
by multiple factors such as inflammatory mediators (IL-1β, IL-6, IL-8, and TNF-α), gut microbiota profile,
neuropeptides and serotonin pathway, stress hormones and nutritional substances. Neuropeptides including CGRP,
SP, VIP, NPY are thought to have antimicrobial impact on a variety of the gut bacterial strains and thus speculated
to be involved in the bidirectional relationship between the gut and the brain. According to the current
knowledge, migraine headache in patients harboring HP might be improved following the bacteria eradication.
Migraineurs with long headache history and high headache frequency have a higher chance of being diagnosed
with IBS. IBS and migraine share some similarities and can alter gut microflora composition and thereby may affect
the gut-brain axis and inflammatory status. Migraine has been also associated with CD and the condition should be
searched particularly in patients with migraine with occipital and parieto-occipital calcification at brain
neuroimaging. In those patients, gluten-free diet can also be effective in reducing migraine frequency. It has also
been proposed that migraine may be improved by dietary approaches with beneficial effects on gut microbiota
and gut-brain axis including appropriate consumption of fiber per day, adhering to a low glycemic index diet,
supplementation with vitamin D, omega-3 and probiotics as well as weight loss dietary plans for overweight and
obese patients.
Introduction
Based on global burden of headache reports in 2016, it
was estimated that approximately 14% of the adult popu-
lation worldwide suffer from migraine [1]. The disease is
three times more prevalent among females and imposes
high burden at the individual and society level. According
to Global Burden of Disease (GBD) study 2018, migraine
has been recognized as the first leading cause of disability
in those aged less than 50 years [2, 3]. The exact patho-
genesis of migraine is still undefined but implies numer-
ous factors, including the gut-brain axis [4].
The terminology “gut-brain axis “points out a bidirec-
tional relationship between the GI system and the central
nervous system (CNS). Brain normally regulates move-
ments and functions of the GI tract (sensory and secretion).
Hormonal factors through the hypothalamic pituitary ad-
renal (HPA) axis by mediating stress responses impact on
the gut functions. On the other hand, GI system is believed
to be able to affect the CNS. A number of the brain func-
tions such as cognition, behavior and even nociception are
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under the influence of the gut system [5, 6]. The dysfunc-
tion of the gut-brain axis has been implicated in a number
of neurological disorders such as multiple sclerosis, mood
and anxiety disorders, Alzheimer disease, Parkinson disease,
and migraine [5, 6]. Figure 1 depicts the mechanisms of the
bidirectional relationship between the gut and the brain in
migraine (Fig. 1). Several neurotransmitters have been sup-
posed to play a role in this process including serotonin,
dopamine, gamma-aminobutyric acid, and calcitonin gene-
related peptide (CGRP) [6–8].
The present review article aims to discuss the direct and
indirect evidence suggesting relationships between migraine
and the gut-brain axis. As it will be clarified later, this inter-
relationship seems to be influenced by multiple factors such
as inflammatory mediators, gut microbiota profile, neuro-
peptides, stress hormones and nutritional substances. In
this regard, at first we will take a look at the involvement of
inflammation in migraine headache and role of gut micro-
biome. Afterwards, the role of the neuropeptides specifically
serotonin pathway in relation to migraine and gut-brain
axis will be explored. Later, the current evidence on the as-
sociation between migraine and gastrointestinal (GI) disor-
ders including Helicobacter pylori (HP) infection, irritable
bowel syndrome (IBS), celiac disease (CD) and inflamma-
tory bowel disease (IBD) will be described. Finally, the ef-
fects of probiotic supplementation on migraine and
possibly effective dietary approaches for migraine patients
including modifying carbohydrate and fat intake, vitamin
supplementation and weight loss diets will be discussed.
The involvement of inflammation in migraine headache
and role of gut microbiome
In the gut, immune cells and their inflammatory mediators
such as interleukin (IL)-1β, IL-6 and IL-18, tumor necrosis
factor alpha (TNF- ), and interferon gamma (IFN)-
have been implicated as sensitizers of afferent endings and
are known as inducers of visceral pain [9, 10]. Additionally,
proinflammatory cytokines, including IL-1β, IL-6, IL-8, and
TNF-α have been implicated in migraine pain and are in-
creased during migraine attacks [11, 12].
Most of the studies aiming to investigate the roles of gut
microflora in different disorders, usually use microbiota
deprivation or “germ-free” murine models. These animals
are grown in a sterile condition and therefore are
microbiota-deficient [13]. In this regard, the importance
of the immune system in the gut-brain axis and in mi-
graine pathobiology is also supported by the evidence that
hypernociception caused by inflammatory stimuli can de-
crease in germ-free compared to conventional mice [14].
This result highlights the important role played by gut
microbiota in preparing the host adaptation to stress fac-
tors in the environment, which induce pain [14].
It is noteworthy that the composition of the gut micro-
biota plays a major role in gut-brain axis. This happens via
two mechanisms: indirect signaling, including microbiota-
derived neurotransmitters, inflammatory molecules, and
hormones; and direct connection with stimulating end
terminals of the vagus nerve (Fig. 2). Also in this case, the
mechanism is bidirectional as CNS can modulate gut
microbiota throughout sympathetic and parasympathetic
systems and by releasing neuroendocrine peptides [15].
Changes in the intestinal microbiota profile may occur as
a result of psychological and physical stress factors. These
stressors stimulate release of corticotrophin-releasing hor-
mone in hypothalamus, that induces cortisol secretion
from the adrenal glands, and may lead to alterations in the
permeability of the intestines through changing the micro-
biota profile. Finally these events could lead to dysbiosis
Fig. 1 Gut -Brain Axis. CNS, Central nervous system; ENS, Enteric nervous system; GI, Gastrointestinal
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(changes in microbiota profile of the gut) [6, 16–19]. On
the other hand, dysbiosis of GI microbiota and increased gut
permeability may lead to activation of HPA axis through the
release of proinflammatory cytokines such as IL-1β and
TNF- . The release of cytokines may be inhibited by the
stress-induced steroid response which anyhow increases the
susceptibility of inflammatory disorders [20–23].
Substances such as CGRP, substance P (SP), vasoactive
intestinal peptide (VIP), and neuropeptide Y (NPY), are
thought to have antimicrobial impact on a variety of the
gut bacterial strains (for instance Escherichia coli, Entero-
coccus faecalis, and Lactobacillus acidophilus) and thus
speculated to be involved in the bidirectional relationship
between the gut and the brain [15]. It has also been re-
ported that the colonic concentration of SP increases in
response to antibiotic treatment and subsequent dysbiosis
while Lactobacillus paracasei administration attenuated
this response [24]. Studies of peripherally administrated
CGRP in animal models demonstrated CGRP inhibits
basal and stimulated gastric acid secretion [25, 26]. In
addition, CGRP is a potent inhibitor of pancreatic enzyme
secretion via modulation of a central vagal out flow [27].
On the other hand, as CGRP signaling could be influenced
by microbiota [15].
Nutritional factors may influence the mechanisms
through which the gut microbiota manages gut health
and immune function [28]. Short-chain fatty acids
(SCFAs, namely: butyrate, propionate, and acetoacetate)
are crucial in maintaining gut barrier integrity. These
substances are produced by bacteria in the distal colon
[29–32]. It has been suggested that gut microbiota
activities and consequently the levels of SCFAs in the
gut might be affected by dietary factors including fiber
and probiotics [31]. Apart from affecting gut/systemic
immunity, SCFAs bypass portal circulation and could
reach the CNS via circulation. In CNS, SCFAs have neu-
roprotective properties. For instance, sodium butyrate,
the salt of butyrate, stimulates cell proliferation and dif-
ferentiation in the dentate gyrus, and enhances the ex-
pression of brain-derived neurotrophic factor (BDNF)
and glial-derived neurotrophic factor (GDNF). Butyrate
also shows anti-inflammatory effect in the brain by sup-
pressing the synthesis of TNF-α, induced by the endo-
toxin lipopolysaccharides (LPS) through the suppression
of nuclear factor κB [32]. Additionally, changes in SCFAs
producing phyla can affect immune function of the host.
Rapid and extreme dietary changes directly affect gut
microbiota because they influence the beta diversity of
the gut microbiota (scale of measuring the turnover of
the microbiota species) [33, 34]. Interestingly, adding
prebiotics (fermentable fibers) to high-fat diet was
reported to restore the decreased levels of butyrate-
producing bacteria and Bifidobacteria which also high-
lights the critical influence of diet on composition of the
gut microbiota [35].
Therefore, due to the bidirectional association between
permeability of the gut and inflammatory state, aug-
mented gut permeability can stimulate inflammatory
and immune responses through LPS leakage and subse-
quently proinflammatory cytokines can reinforce gut
permeability [36, 37]. On the other hand, as mentioned,
proinflammatory cytokines such as TNF-α, IL-1β and
Fig. 2 Mechanisms of the effects of gut bacteria in keeping normal balance of gut-brain axis via indirect signaling. CGRP, Calcitonin gene-related
peptide; CRH, Corticotrophin-releasing hormone; HPA, Hypothalamic pituitary adrenal axis; LPS, lipopolysaccharides; IL, Interleukin; TNFa, Tumor
necrosis factor alpha
Arzani et al. The Journal of Headache and Pain           (2020) 21:15 Page 3 of 12
IL-6 could also affect nociceptive responses in the tri-
geminal pathway and play a role in migraine pain initi-
ation [38–43]. Figure 2 demonstrates the mechanisms of
the effects of gut bacteria in keeping normal balance of
gut-brain axis via indirect signaling in which these in-
flammatory cytokines play an important role.
The role of the neuropeptides in migraine headache with a
focus on the gut-brain axis
Glutamate, as an excitatory neurotransmitter, plays a
role in migraine pathophysiology through different ef-
fects including cortical spreading depression (CSD), cen-
tral sensitization, and by stimulating trigeminovascular
system. Increased glutamate levels in the plasma and
CSF of migraineurs in comparison with control subjects
have been reported previously [44, 45]. On the other
hand, the role of this neurotransmitter in the enteric
nervous system (ENS) and the gut-brain axis (transmit-
ted along afferent neurons from the gut into the brain)
has been studied in depth. Also, it was indicated that
glutamate might affect the inflammation and oxidative
stress in the GI tract [46]. The disturbances in glutamate
pathway appeared to be involved in the pathogenesis of
a variety of GI disorders such as IBD, IBS, gastroesopha-
geal reflux, gastric acid hyper-secretory disorder [46].
NPY, a probable indicator of noradrenergic system
function, affects cerebral blood flow through cerebral
circulation regulation. It is worth mentioning that higher
levels of NPY has been detected in ictal phases of
migraineurs [15, 44]. Interestingly, this neurotransmitter
has been detected at all levels of the gut-brain axis. NPY
pathway is also assumed to contribute to changing GI
function and its blood flow, immunological system and
inflammation status, pain, homeostasis of energy, emo-
tion, mood, as well as behavior and other functions of
the brain (e.g. cognition) [15, 44, 47].
One of the main biomarkers of migraine, CGRP, inhibits
gastric acid secretion and may suppress food intake [48].
As mentioned, CGRP signaling could be influenced by
microbiota as such increased level of this neurotransmitter
in dysbiosis might be one of the probable justification for
prescribing probiotics in migraine [15].
Cholecystokinin (CCK) is synthesized by enteroendocrine
cells in the mucosal lining of small intestine (I cells), mam-
malian brain (eg. cortex, thalamus, mesolimbic, periaqui-
ductal gray matter (PAG) and midbrain), and spinal cord.
This peptide inhibits gastric emptying and acid secretion,
stimulates gall bladder contraction and pancreatic secre-
tion, and provokes satiety feeling in the brain via CCK1 re-
ceptor. The presence of CCK1R on vagal afferent terminals
lying in the wall of GI tract further confirms the hypothesis
of endocrine and paracrine collaboration. The location of
CCK1R in mesolimbic structures, hypothalamus and brain
stem nucleus and its interaction with dopamine, serotonin,
glutamate, hypothalamic hormones, and neuropeptides ex-
plains specific roles of CCK in behavior, mood, and extra-
pyramidal function [49, 50]. Like CGRP, CCK is produced
in the PAG and may be responsible for endogenous pain
signaling system and its level increases in migraine [51].
CCK is also present in trigeminal ganglion, such that stimu-
lation of trigeminal ganglion results in increasing local CCK
[52]. On the other hand, obese patients had a significantly
higher frequency and severity of migraine attacks as com-
pared to overweight or normal weight individuals [53]. A
meta-analysis study found an increased risk of having mi-
graine in obese subjects; also the risk of chronic migraine is
higher in obese subjects than in normal weight group [54].
One of the possible explanations for the association be-
tween migraine and obesity is CCK secretion in response to
high fat diets as intra-duodenal free fatty acids stimulate
CCK secretion [55].
Serotonin pathway involvement in migraine headache with
a focus on the gut-brain axis
It has been proposed that tryptophan-kynurenine path-
way might be one of the main ways by which GI micro-
biota may affect the function of the CNS due to the
presence of synthetic enzymes in bacterial strains of the
intestine that may produce tryptophan metabolites (such
as quinolinic and kynurenic acids) [16, 56]. As trypto-
phan is the precursor of serotonin, the amount of this
neurotransmitter in the brain depends on hthe levels of
this amino acid [16, 56].
The role of gut microbiota in anxiety, depression and
the HPA axis has been studied through assessing the ef-
fects of prebiotics and probiotics administration in these
conditions [57–59]. It has been reported that “germ-free”
mice may have increased plasma levels of serotonin and
tryptophan. These reports may justify the role played by
hormonal factors in the association between gut bacterial
strains and tryptophan levels [16, 56, 60]. Moreover, the
turn-over of serotonin as shown by increased levels of the
pathway metabolites, has been reported to be elevated in
germ-free animals; while it has been demonstrated that
supplementation with probiotic lead to lessen the concen-
tration of 5-hydroxyindoleacetic acid (5-HIAA) and
kynurenine in the cortical frontal lobe. These effects might
be attributed to the impact of the gut microbiota on the
enzymes affecting availability of tryptophan and serotonin
pathway and the amino acid utilization by the bacteria
[61]; however, the exact mechanisms and the role of dif-
ferent factors including gender, and strains of mice have
not been elucidated yet.
Moreover, the presence of serotonin receptors on im-
mune cells including monocytes, macrophages, lympho-
cytes, and dendritic cells, may shed light on the impact of
this neurotransmitter on immune modulation. This issue
might also explain effects of serotonin on inflammatory
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state of the intestine and its role in increasing the suscep-
tibility for GI diseases (such as Crohn’s disease, ulcerative
colitis, celiac disease and diverticulitis) [61].
Migraine and gastrointestinal disorders
To date, several researches have shown that migraine is
associated with some GI disturbances such as diarrhea,
constipation [62, 63], dyspepsia [64], and gastroesophageal
reflux (GERD) [65]. Additionally, some GI disorders in-
cluding HP infection [66, 67], IBS [68, 69], CD [70], and
IBD [71–73] have also been associated with migraine.
Helicobacter pylori infection
Based on the findings of a meta-analysis of 5 case-
control studies, about 45% of migraineurs harbor HP,
while the prevalence rate among healthy controls was es-
timated at about 33% [66]. It is noteworthy that when
aiming at investigating the role of HP infection in head-
ache pathogenesis, various strains of the bacterium, eth-
nicity of the studied patients, the variation of HP in
different regions, and the potential pathological differ-
ences which would be present in different subtypes of
headache, should be considered [18].
According to a review article findings, evidence sup-
ported that HP eradication may be associated with relief
of migraine symptoms [67]. Also, Faraji et al. 2012 [74]
compared the effects of HP eradication treatment with
placebo among patients who received migraine treatment
within a randomized, double-blind, controlled trial. They
reported that at the end of study, patients who received
HP eradication treatment showed lower migraine-related
disability level compared with those in placebo group [74].
HP infection is supposed to be related to a persistent
chronic inflammatory state, which in turn may lead to
increased production of inflammatory mediators and
vasoactive compounds [18, 75]. Therefore, the proposed
mechanism for the association between migraine and
HP infection may include induced immune, inflamma-
tory, and vascular responses and subsequent release of
immune cells, inflammatory and vasoactive agents into
the gastric mucosa that may finally lead to hypersensitiv-
ity of brain pain-sensitive structures [66]. Moreover, the
neuroendocrine release of other factors involved in mi-
graine pathophysiology including serotonin, SP, and VIP
appeared to be altered by the inflammatory state caused
by the bacterium [66]. Particularly, it has been demon-
strated that the levels of CGRP were elevated in HP-
induced duodenal ulcers when comparing to healthy
individuals [18, 44, 76]. Furthermore, higher IL-10
plasma levels have been observed during migraine at-
tacks [77]; on the other hand, some studies showed that
HP infection is associated with increased levels of IL-12
and IL-10 [78–80]. These observations may suggest that
IL-10 stimulated by HP may exacerbate the severity of
migraine.
Collectively available data indicate that HP may impact
on migraine symptoms. However, at the moment this is
still a matter of research and there is no evidence to sup-
port systematic search of the infection in migraineurs
nor the treatment of the infection specifically aimed to
improve migraine symptoms.
Irritable bowel syndrome
IBS and migraine share some similarities, i.e. both disor-
ders are chronic, recurrent [69], and more prevalent
among women, have high individual/social burden,
highly affect the patients’ quality of life, and seem to be
accompanied by a number of comorbid psychological
diseases especially anxiety [69, 81–85]. Furthermore,
central, visceral and thermal cutaneous hypersensitiza-
tion are common among both disorders [69]. Overall,
60% of migraineurs have allodynia and IBS patients re-
ported to have allodynia aside from visceral hypersensi-
tivity [69]. N-methyl-D-aspartate (NMDA) may probably
be responsible for allodynia among the IBS patients [86].
There is an established association between migraine
and IBS, such that IBS was revealed to be common
among migraineurs and migraine was reported to be
prevalent among IBS suffers [18]. A prevalence cohort
study showed that in comparison to non-IBS subjects,
IBS patients had a 40–80% higher prevalence odds of
migraine, depression, and fibromyalgia [68]. A further
study, found that about 17% of IBS patients had mi-
graine while only 8% of the control group suffered from
this type of headache [87]. A meta-analysis on 6 studies
showed that individuals who suffered from IBS had
coexisting headache with an estimated OR of approxi-
mately 2.7 [69]. On the other hand, higher prevalence of
IBS in migraineurs has been also reported with a rate
ranging from 4% to 40% [69, 81–85]. Migraineurs with
long headache history and high headache frequency had
a higher chance of being diagnosed with IBS [88].
Mechanisms underlying the association are not en-
tirely clear. Similar to migraine, IBS can alter gut micro-
flora composition and thereby may affect the gut-brain
axis and inflammatory status [13, 89–93]. Moreover,
food allergies/intolerances that seem to cause migraine
attack initiation and relapse of IBS may also explain the
association between the disorders [92]. With respect to
this, food elimination diets based on IgG antibodies may
effectively reduce symptoms in migraine patients with
concomitant IBS [94]. Hereditary and genetic poly-
morphism might explain at least in part the comorbidity
between migraine and IBS [69].
Also 5H-T has been postulated to play a role in the as-
sociation of migraine and IBS. Serotonin release from
entrochromaffin cells in the gastric pits of the stomach
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luminal epithelium stimulates gastric acid secretion, sen-
sory and motor GI reflexes which in turn activates the
ENS [69, 95, 96]. Interestingly, it was observed that patients
with IBS had higher systemic levels of serotonin and kynure-
nic acid when compared to healthy individuals, which im-
plies that serotonin function in these patients might be
impaired as a result of augmented kynurenic pathway activa-
tion [18, 61]. Therapeutic agents modulating serotonin re-
ceptors are effective in patients with both disorders (i.e. IBS
and migraine) [97]. Sexual hormones are also believed to
play a role, because migraine and IBS are more prevalent
among females. In addition, estrogen enhances serotonin re-
lease in the brain and increases pain sensitivity [98].
Celiac disease
CD is an autoimmune multisystem condition caused by
gluten peptide in genetically susceptible individuals [99].
According to the available data, the prevalence of CD is
1.4% [100]. A variety of neurologic manifestations have
been observed with CD such as epilepsy, ataxia, cerebellar
ataxia, mood disorders, encephalitis, peripheral neuropathy,
neuromuscular disorders, dementia, learning disorders,
developmental delay and migraine [101]. A “nutritional-mi-
crobial-epithelial-neuronal” akin to “environmental-lu-
minal-mucosal-neuronal” brain network may be
responsible for these extra-intestinal manifestations [102].
Studies have shown that patients with CD have higher
prevalence of migraine compared with healthy controls and
vice versa [103, 104]. It is estimated that about 21–28% of
patients with CD have migraine [104–106]. Migraine-like
headache may represent the initial feature of CD [103,
107–109]. Some studies suggest that evidence of occipital
and parieto-occipital calcifications and white matter abnor-
malities at brain neuroimaging are associated with comor-
bid CD in subjects with migraine [103, 110–112]. Clinicians
may consider to search for CD in subjects with migraine in
the presence of such alterations especially if other symp-
toms suggestive of CD are present. The association between
migraine and CD may be attributed to several concurrent
mechanisms including proinflammatory cytokines induced
by gluten (e.g. IFN- and TNF- that are thought to en-
hance CGRP levels), lack of vitamins and macro elements
due to malabsorption, vascular tone disturbances, nervous
system hypersensitivity, brain hypoperfusion and perivascu-
lar inflammation [18, 103, 113–117]. It was also suggested
that CD treatment may improve headache [118]. There are
some studies which suggest that institution of gluten-free
diet also may be effective in decrease of migraine frequen-
cies [18, 103, 119].
Inflammatory bowel disease
IBD is a chronic relapsing-remitting inflammatory condi-
tion that consists of Crohn disease and ulcerative colitis
[120]. Data about possible relationship between headache
or migraine and IBD are scarce [19]. A case-control study
showed that the prevalence of headache was higher in IBD
individuals compared to control group (46% vs 7%) [71].
In a Brazilian study, headache was the most common
neurologic manifestation in IBD patients; 25% of patients
with headache fulfilled the criteria for migraine [72]. A
cross-sectional study performed in a tertiary-care headache
center demonstrated that migraine prevalence was two-fold
higher in IBD individuals compared to general population
[73]. A further study reported a higher prevalence of mi-
graine in patients with IBD (21.3%) compared to non-IBD
subjects (8.8%) [121]. Although the exact mechanism
remained unclear, but autoimmune-inflammatory responses,
malabsorption, endothelial dysfunction that are present in
IBD as well as immunosuppressive treatments prescribed for
the disorder might be involved in pathophysiology under-
lying the association between IBD and migraine [121–123].
Dietary approaches in migraine headache with a focus on
the gut-brain Axis
Different dietary approaches have been suggested for
subjects with migraine [117], but at the moment it is un-
clear if any diet can be used to improve migraine man-
agement. It is important that those studies are very
difficult to put into context because difficulties in main-
taining the dietary strategy, in establishing adherence to
the regimen, and in blindness in the study design. Over-
all, there is lack of high quality, well-designed clinical
trials in this field, and available data are preliminary and
should be interpreted with caution.
Probiotic supplementation
Probiotic supplementation may modulate migraine at-
tacks. Possible mechanisms of action are unclear and in-
clude promoting SCFA production in the gut and
improving epithelial integrity of the intestine and enhan-
cing inflammation by nuclear factor kappa-B (NF-κB)
pathway suppression and therefore lowering proinflamma-
tory cytokines levels [37, 89, 90, 124–127]. Probiotics
could also enhance the gastric emptying rate and attenu-
ate gastric stasis - a common GI complaint among migrai-
neurs - by neuroimmune interaction [91, 128, 129].
Some studies have explored the beneficial effects of
probiotic administration on migraine headaches [89,
126, 127, 130]. In a randomized double-blind controlled
trial, the effect of daily adminstration of a 14-strain-
probiotic mixture or placebo for 8 weeks in chronic and
10 weeks in episodic migraineurs was evaluated. Pro-
biotic administration resulted in significant improve-
ments in frequency and severity of migraine and the
consumption of abortive medications in the studied
population despite no significant changes in serum levels
of selected inflammatory biomarkers [127].
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In an open-label trial in 40 migraineurs, 12-week sup-
plementation with probiotic + minerals + vitamins +
herbs, resulted in significant improvement in patients
quality of life in approximately 80% of the subjects and
pain relief in more than half of the migraineurs [126]. In a
further study, supplementation with a probiotic mixture
of 7 bacterial strains reduced the migraine attacks fre-
quency by about a quarter and also lowered migraine-
related disability [89]. However, a more recent study by
the same group of authors reported conflicting results and
found no changes in migraine-related outcomes with the
same treatment [93]. The studied that were performed on
effects of probiotic supplementation on migraine head-
ache are summarized in Table 1.
Carbohydrate
Gut microbiota fermented resistance carbohydrate to dif-
ferent metabolites, such as SCFAs [131]. The dietary shift
to high resistance polysaccharides increases SCFAs levels
[28]. In a randomized clinical study, 350 migraineurs were
allocated to low glycemic index diet (considered as a high-
fiber intake) group or to prophylactic medications group
(either propranolol, flunarazine, amitriptyline or topira-
mate) in a 1:1 ratio. One month after dietary restrictions,
the frequency of attacks was significantly reduced in both
the diet and the pharmacological group. The befit was
maintained at 90-day. Severity of attacks was reduced at
both 30- and 90-day in the drug group but only at 90-day
in the diet group [132].
Fat
Chronic exposure to omega-3 in utero and early life, in-
creases the proliferation of Lactobacillus and Bifidobacterium
and sp., results in more SCFAs production [133]. Four stud-
ies assessed the effect of low-fat diets in migraine prophy-
laxis. Reducing dietary fat intake for three months resulted
in the reduction in headache intensity, frequency and abort-
ive medicine consumption [53, 134–136]. In a 12-week trial
adults with chronic migraine randomly assigned to have high
omega-3/low omega-6 diet or low omega-6 diet. Individuals
on high omega-3/low omega-6 diet experienced higher im-
provement in their headache compared to migraineurs on
low omega-6 diet [134]. The observed effect was attributed
to the followings [117]: [1] the balance between the two ei-
cosanoid pathways, omega-6 and omega-3, contribute to in-
flammation control [2]; omega-6 fatty acids promote
vasodilation [3]; high-fat diet induces hypercoagulability [4];
dietary fat affects serotonin release from platelet. Although
high-fat diet reduces the proliferation of the SCFAs produ-
cing bacteria, the effect of fat intake on gut microflora and
SCFAs production in migraineurs was not addressed yet in
the studies. Table 2 represents a summary of the studies
were conducted on effects of low fat diet on migraine
headache.
Vitamins
Vitamin D3 supplementation affected the intestinal micro-
biota composition. Supplementing healthy individuals
with vitamin D3 for 8 weeks also significantly reduced
Helicobacter sp. count [137]. Several studies reported that
serum levels of vitamin D might be associated with in-
creased risk of migraine/headache [138, 139]. Further, it
has been suggested that the prevalence of deficiency/insuf-
ficiency of this vitamin may be higher in patients who suf-
fer from migraine/ headache when comparing to
headache-free individuals [139]. Also favorable effects of
Table 1 Literatures on effects of probiotic supplementation on migraine headache
authors and year Type of article Sample size Type of probiotics Duration
of
treatment
Results
De Roos N, Giezenaar C, Rovers
J, et al. 2015 [89]
Clinical trial 29 patients 2 g/d of a probiotic food
supplement (Ecologic(®)Barrier,
2.5 × 10(9) cfu/g)
12 weeks 1) number of migraine days/month
decreased significantly
2) The MIDAS score improved
3) Headache Disability Inventory
(HDI) did not change significantly
de Roos N, van Hemert S,
Rovers J, et al. 2017 [130]
Randomized
control trial
63 patients
(probiotic (n = 31)
placebo group
(n = 32))
multispecies probiotic (5 × 109
colony-forming units) or
placebo daily
12 weeks No significant benefit from a
multispecies probiotic compared
to a placebo on the outcome
parameters of migraine and
intestinal integrity
James Sensenig N, Jeffrey
Marrongelle D and CCN MJ S. T.
2001 [126]
Clinical trial 40 patients Two nutritional formulations
contained probiotics +
minerals + vitamins + herbs
3 months 80% of the participants experienced
significant improvements in quality
of life and pain relief in more than
half of the migraineurs
Martami F, Togha M,
Seifishahpar M, et al. 2019 [127]
randomized
double-blind
controlled trial
40 episodic and
39 chronic
migraine patients
14-strain probiotic mixture
or placebo
10 weeks Significant reduction in migraine
attacks, migraine severity, and the
number of abortive drugs in the
probiotic group compare to the
placebo group
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vitamin D supplementation on intensity and frequency of
migraine attacks have been reported [139].
Weight loss approaches in migraine/headache
Animal studies showed that obesity reduced gut perme-
ability, reduced expression of tight junctions and could
influence intestinal microbiota composition [140]. Pieces
of evidence showed that obesity could increase the risk
of episodic and chronic migraine [54, 141] while weight
reduction can decrease the intensity, frequency, and dur-
ation of migraine headache in adults [142–144] and ado-
lescents [145]. The link between obesity and headache
was proposed to be attributed to shared pathophysio-
logical features. Evidence showed an increase in CGRP
plasma level of adult with obesity which is also pointed
out in patients with migraine [146]. Furthermore, a rise
in proinflammatory cytokines, such as IL-6 and TNF-
was reported in obese individuals and at the acute head-
ache onset [147]. A summary of the studies on effects of
weight loss on migraine headache is shown in Table 3.
Conclusion
The current evidence shows that the gut-brain axis may
impact on migraine despite the mechanism explaining
this interaction is not entirely clear. Generally, this inter-
action seems to be influenced by multiple factors such
as inflammatory mediators (IL-1β, IL-6, IL-8, and TNF-
α), gut microbiota profile, neuropeptides and serotonin
pathway, stress hormones and nutritional substances.
Neuropeptides including CGRP, SP, VIP, NPY are
thought to have antimicrobial impact on a variety of the
gut bacterial strains and thus speculated to be involved
in the bidirectional relationship between the gut and the
brain. Additionally, there is comorbidity between mi-
graine and a number of conditions including HP infec-
tion, IBS, IBD, and CD. According to the current
knowledge, migraine headache in patients harboring HP
might be improved following the bacteria eradication.
Migraineurs with long headache history and high head-
ache frequency have a higher chance of being diagnosed
with IBS. IBS and migraine share some similarities and
Table 2 Literatures on effects of low fat diet on migraine headache
Authors and year Type of
article
Sample size Type of diet Duration of
treatment
Results
Ferrara LA, Pacioni D, Di Fronzo
V, Russo BF, Speranza E, Carlino
V, et al. 2015 [53]
Crossover
intervention
trial
83 episodic or chronic
migraineurs (63 female
and 20 male)
a low-lipid and a normal-lipid
diet
3 months + 3
months
Significant reduction in
severity and number of
migraine attacks
Ramsden CE, Zamora D, Faurot
KR, et al. 2013
randomized
trial
67 patients with
chronic daily
headache
(H3-L6 = 33, L6 = 34)
High omega-3 + low omega-6
fatty acid (H3-L6) or low
omega-6 fatty acid (L6)
12 weeks Significant reduction in
HIT score, headaches day
per month, and headache
hours per day in H3-L6
group
Bic Z, Blix GG, Hopp HP, Leslie
FM, Schell MJ. 1999 [135]
Clinical trial 54 migraineurs limit fat intake to no more
than 20 g/day
12 weeks Significant decrease in
headache frequency,
intensity, and duration
and medication intake
Bunner AE, Agarwal U, Gonzales
JF, Valente F, Barnard ND. 2014
Crossover
trial
42 migraineurs dietary instruction (a low-fat
vegan diet) and placebo
supplement
36 weeks (16
weeks + 4
weeks washout+
16 weeks)
Significant reduction in
headache severity and
frequency during the
diet period
Table 3 Literatures on effects of weight loss on migraine headache
authors and year Type of
article
Sample size Type of intervention Duration
of
treatment
Results
Bond DS, Vithiananthan S, Nash JM,
Thomas JG, Wing RR. 2011 [142]
Prospected
observational
study
24 migraineurs Bariatric surgery 6 months Significant reduction in
headache severity, and
headache-related disability
Novack V, Fuchs L, Lantsberg L,
Kama S, Lahoud U, Horev A,
et al. 2011 [143]
Prospective
study
29 premenopausal
obese women with
diagnosis of migraine
Bariatric surgery 6 months Significant reduction in
frequency of migraine attacks,
duration of the attacks, and
medication use during the
attack and improvement of
headache-related disability
post bariatric surgery
Verrotti A, Agostinelli S, D’Egidio C,
Di Fonzo A, Carotenuto M, Parisi P,
et al. 2013 [145]
Clinical trial 135 obese
adolescent
migraineurs
dietary education, specific
physical training, and
behavioral treatment
12
months
Significant decrease in headache
frequency and intensity, use of
acute medications, and disability
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can alter gut microflora composition and thereby may
affect the gut-brain axis and inflammatory status. Mi-
graine has been also associated with CD and the condi-
tion should be searched particularly in patients with
migraine with occipital and parieto-occipital calcification
at brain neuroimaging. In those patients, gluten-free diet
can also be effective in reducing migraine frequency.
Diet strategies may impact on migraine course and could
represent a valuable instrument to improve migraine
management. However, no definite conclusion can be
drawn because of the limited evidence on migraine man-
agement with diet. It can be hypothesized that prescrib-
ing dietary approaches with beneficial effects on gut
microbiota and gut-brain axis including appropriate con-
sumption of fiber per day, adhering to a low glycemic
index diet, supplementation with vitamin D, omega-3
and probiotics as well as weight loss dietary plans (in
case of obese patients) could lead to improvements in
migraine associated features.
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